证券简称：国新健康 证券代码：000503 编号：2024-72 国新健康保障服务集团股份有限公司 关于总法律顾问辞职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国新健康保障服务集团股份有限公司（以下简称"公司"）董事会近日收到 公司总法律顾问王中胜先生递交的书面辞职报告。王中胜先生因个人原因，申请 辞去公司总法律顾问职务，辞职后不再担任公司及其控股子公司任何职务。 根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引第 1号——主板上市公司规范运作》等法律法规和《公司章程》的规定，王中胜先 生的辞职报告自送达董事会之日起生效。截至本公告披露日，王中胜先生因股权 激励计划持有公司已获授但尚未解锁的限制性股票51,000股，后续将按照《上市 公司股权激励管理办法》、公司《限制性股票激励计划（第一期）》的相关规定 处理。 特此公告。 国新健康保障服务集团股份有限公司 董 事 会 二零二四年十月二十八日 王中胜先生在公司任职期间，勤勉尽责、恪尽职守，为公司发展做出重大贡 献。在此，公司及董事会对王中胜先生任职期间为公司发展所付出的努力和做出 ...

Investment Rating - The report maintains a "Buy" rating for the company [1][2] Core Views - The company's revenue for the first three quarters of 2024 reached 200 million yuan, representing a year-on-year growth of 24.4%, while the net profit attributable to shareholders was a loss of 31 million yuan, narrowing the loss by 71.5% year-on-year, in line with market expectations [1][2] - The company experienced steady revenue growth, with Q3 2024 single-quarter revenue of 63 million yuan, a year-on-year increase of 3.28%, and a significant net profit increase of 278% year-on-year due to investment gains from the sale of Hainan Chemical Fiber equity [1][2] - The company is expected to benefit from the recent top-level design for public data resource development and utilization, which aims to enhance the digital economy and public data infrastructure [2] - The DRG/DIP reform is anticipated to accelerate the company's medical insurance information technology business, with several successful bids for projects in various regions [2] - The company is projected to have EPS of -0.06, -0.02, and 0.06 yuan for 2024, 2025, and 2026 respectively, indicating a positive outlook supported by its backing from a major state-owned enterprise [2] Financial Summary - Total revenue (in million yuan) is forecasted to grow from 330.13 in 2023 to 402.51 in 2024, with a year-on-year growth rate of 21.93% [1][8] - The net profit attributable to shareholders is expected to improve from a loss of 79.79 million yuan in 2023 to a loss of 55.64 million yuan in 2024, with a year-on-year growth rate of 30.27% [1][8] - The company's operating cash flow is projected to improve from a loss of 102 million yuan in 2023 to a loss of 8 million yuan in 2024 [9]

Financial Performance - The company's operating revenue for Q3 2024 was ¥62,782,414.54, representing a 3.28% increase year-over-year, while the year-to-date revenue reached ¥200,175,797.05, up 24.40% compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2024 was ¥42,034,817.87, a significant increase of 278.17% year-over-year, while the year-to-date net profit was -¥30,946,674.76, showing a 71.49% improvement compared to the previous year[2]. - Basic earnings per share for Q3 2024 were ¥0.0429, reflecting a 263.22% increase year-over-year, and diluted earnings per share were also ¥0.0429, with a similar increase of 263.84%[2]. - Total operating revenue for Q3 2024 reached ¥200,175,797.05, an increase of 24.4% compared to ¥160,912,265.05 in Q3 2023[14]. - Net profit for Q3 2024 was a loss of ¥32,037,786.21, compared to a loss of ¥108,563,724.01 in Q3 2023, showing an improvement[15]. - Basic and diluted earnings per share for the period were -0.0316 CNY, improving from -0.1208 CNY year-over-year[16]. Assets and Liabilities - The total assets at the end of Q3 2024 amounted to ¥1,852,171,349.22, a decrease of 5.09% from the end of the previous year[2]. - The company's total assets decreased to ¥1,852,171,349.22 from ¥1,951,543,466.24, a decline of 5.1%[14]. - Current liabilities totaled ¥461,187,093.81, down 12.7% from ¥528,756,399.25 in the previous year[14]. - Long-term liabilities amounted to ¥1,350,562.58, a decrease of 6.4% from ¥1,442,728.64[14]. - The total equity attributable to shareholders of the parent company decreased to ¥1,389,631,691.42 from ¥1,420,251,225.49, a decline of 2.2%[14]. Cash Flow - The net cash flow from operating activities for the year-to-date period was -¥142,513,222.03, which represents an 8.91% improvement compared to the previous year[2]. - Cash flow from operating activities showed a net outflow of -142,513,222.03 CNY, an improvement from -156,453,628.26 CNY in the previous year[17]. - Total cash outflow for operating activities was 360,014,796.97 CNY, compared to 344,961,882.37 CNY in the same period last year[17]. - The company reported cash and cash equivalents at the end of the period amounting to 818,008,502.90 CNY, down from 87,594,099.19 CNY year-over-year[18]. - Cash inflow from investment activities was 112,429,985.00 CNY, compared to 119,261.06 CNY in the previous year[18]. - Cash flow from financing activities resulted in a net outflow of -26,014,871.78 CNY, contrasting with a net inflow of 115,102,854.48 CNY in the same period last year[18]. Investment and Income - The company's investment income for the year-to-date period was ¥72,827,431.33, a remarkable increase of 1850.37% year-over-year, primarily due to the disposal of Hainan Chemical Fiber equity[5]. - The company reported investment income of ¥72,827,431.33, significantly higher than ¥3,734,031.81 in the previous year[15]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 50,724[7]. - The largest shareholder, China Oceanwide Holdings Group Co., Ltd., holds 24.02% of shares, totaling 235,702,593 shares[7]. - The second-largest shareholder, Guoxin Development Investment Management Co., Ltd., holds 2.46% of shares, totaling 24,123,980 shares[7]. - The third-largest shareholder, Hong Kong Central Clearing Limited, holds 1.46% of shares, totaling 14,289,140 shares[7]. - The total number of shares held by the top 10 shareholders includes significant stakes from various institutional and individual investors[7]. - The report indicates that there are no related party relationships among the top 10 shareholders[7]. - The company has not disclosed any participation in securities lending by the top 10 shareholders[7]. - The report does not indicate any changes in the shareholding structure due to securities lending activities[7]. Research and Development - The company's research and development expenses were capitalized during the reporting period, resulting in a 100% decrease in reported R&D expenses compared to the previous year[5]. - Research and development expenses were not reported for Q3 2024, while they were ¥967,945.83 in Q3 2023[15]. Strategic Initiatives - The company is involved in the construction of a commercial insurance data service platform and the upgrade of its marketing network[8]. - The company is focused on enhancing its service capabilities through strategic projects[8]. - The company plans to enhance its digitalization efforts by establishing a Digital Construction Office[10]. - The company has signed a lease for office space in Beijing for a duration of 10 years[10]. - The company has adjusted the implementation subjects of certain fundraising projects to improve the efficiency of fund usage[9]. - The company has signed a tripartite supervision agreement for fundraising due to changes in project implementation subjects[10]. Equity Transactions - The company completed the transfer of 18.96% equity in Hainan Chemical Fiber for a transaction price of RMB 112.4 million[9]. - The company's registered capital increased from RMB 906,413,204 to RMB 984,176,136, with the total number of shares changing from 906,413,204 to 984,176,136[9]. - The company has initiated a buyback and cancellation of 2,863,604 restricted stocks due to unmet performance targets and retirements[11]. Other Financial Metrics - The company received government subsidies amounting to ¥9,240.11 in Q3 2024, primarily for employment stabilization[3]. - The company reported a significant increase in other receivables, which rose by 56.15% to ¥18,215,446.85, attributed to performance bonds and bidding deposits[5]. - Cash and cash equivalents decreased from RMB 928.06 million to RMB 827.69 million[12]. - Accounts receivable increased from RMB 129.56 million to RMB 160.61 million[12]. - The company opened a special settlement account for cash management of temporarily idle raised funds[9]. - The company experienced a foreign exchange loss of -145,922.56 CNY during the period[16].

点赞分享国新健康再度涨停，4个交易日内录得3个涨停，累计涨幅为40.15%，累计换手率为37.49%。 截至10:42，该股今日成交量6854.18万股，成交金额10.96亿元，换手率7.18%。 最新A股总市值达164.08亿元，A股流通市值159.69亿元。 证券时报•数据宝统计，两融数据来看，该股最新（10月22日）两融余额为5.40亿元，其中，融资余额 5.38亿元，较前一个交易日增加567.99万元，环比增长1.07%，近4日累计增加3860.94万元，环比增长 7.73%。 龙虎榜数据显示，该股因连续三个交易日内，涨幅偏离值累计达20%上榜龙虎榜1次，买卖居前营业部 中，机构净卖出5101.95万元，深股通累计净卖出5478.86万元，营业部席位合计净买入1.14亿元。 8月29日公司发布的半年报数据显示，上半年公司共实现营业总收入1.37亿元，同比增长37.23%，实现 净利润-0.73亿元，同比增长14.09%。 （数据宝）近日该股表现日期当日涨跌幅（%）换手率（%）主力资金净流入（万元） 2024.10.225.3411.32-290.432024.10.219.9811.192882.74 ...

股票交易价格异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券简称：国新健康 证券代码：000503 编号：2024-70 国新健康保障服务集团股份有限公司 一、股票交易异常波动情况 四、上市公司认为必要的风险提示 国新健康保障服务集团股份有限公司（以下简称"公司"）股票交易价格连 续 3 个交易日（2024 年 10 月 18 日、2024 年 10 月 21 日、2024 年 10 月 22 日） 内收盘价涨幅偏离值累计达到 20%，根据《深圳证券交易所交易规则》的相关规 定，属于股票交易异常波动的情况。 二、公司关注、核实的情况说明 针对公司股票交易异常波动，公司董事会向公司、控股股东及实际控制人就 相关事项进行了核实，现就有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处。 2、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息。 3、近期公司经营情况及内外部经营环境未发生重大变化。 4、经核查，公司、控股股东和实际控制人不存在关于本公司应披露而未披 露的重大事项，也不存在其他处于筹 ...

证券简称：国新健康 证券代码：000503 编号：2024-69 国新健康保障服务集团股份有限公司 股票交易价格异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动情况 国新健康保障服务集团股份有限公司（以下简称"公司"）股票交易价格连 续 3 个交易日（2024 年 10 月 14 日、2024 年 10 月 15 日、2024 年 10 月 16 日） 内收盘价涨幅偏离值累计达到 20%，根据《深圳证券交易所交易规则》的相关规 定，属于股票交易异常波动的情况。 二、公司关注、核实的情况说明 针对公司股票交易异常波动，公司董事会向公司、控股股东及实际控制人就 相关事项进行了核实，现就有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处。 3、近期公司经营情况及内外部经营环境未发生重大变化。 4、经核查，公司、控股股东和实际控制人不存在关于本公司应披露而未披 露的重大事项，也不存在其他处于筹划阶段的重大事项。 5、经核查，公司控股股东和实际控制人在股票异常波动期间不存在买卖公 司股票的行为。 三、是否存在应披露而未披 ...

Investment Rating - The report assigns a "Buy" rating for the company, marking the first coverage of its stock [3]. Core Insights - Guoxin Health is positioned as a national team in medical insurance IT, focusing on digital healthcare and digital pharmaceuticals, with a strong emphasis on comprehensive management services for medical insurance funds, medical quality safety services, and drug/device regulatory services [2][13]. - The company has rapidly expanded its health service segment, achieving revenue of 4.09 million yuan in 2023 and 22.45 million yuan in the first half of 2024, indicating significant growth [2]. - The recent issuance of public data policies by the central government is expected to catalyze market opportunities, with an estimated market space of at least 100 billion yuan for public data authorization operations [2][23]. - The DRG/DIP payment reform is anticipated to drive upgrades in medical information systems, with Guoxin Health expected to be a core beneficiary due to its leading market share in DRG/DIP services [2][36]. Summary by Sections 1. Medical Insurance IT National Team - Guoxin Health, a state-owned enterprise under China Guoxin Holdings, focuses on digital medical insurance, digital healthcare, and digital pharmaceuticals, providing comprehensive services in medical insurance fund management, medical quality safety, and drug/device regulation [13]. - The company has seen steady revenue growth, with 2023 revenue reaching 330.13 million yuan, and is recovering from previous losses with a gross margin of 24.84% [19]. 2. Public Data Policy Implementation - The central government has issued a series of policies aimed at accelerating the development and utilization of public data resources, which is expected to enhance local and industry execution capabilities [23][25]. - Guoxin Health is well-positioned to benefit from these policies, having already secured public data operation rights in Hangzhou [31]. 3. DRG/DIP 2.0 Plan Release - The DRG/DIP payment reform is entering its 2.0 phase, which will optimize grouping methods and accelerate the transition to new payment standards across various regions [33][36]. - Guoxin Health has a leading market share in DRG/DIP services, having served over 70 regions in DRG and over 40 in DIP, positioning it to benefit significantly from the ongoing reforms [37]. 4. Earnings Forecast and Valuation - The company is expected to achieve revenues of 4.03 billion yuan in 2024, 4.94 billion yuan in 2025, and 6.08 billion yuan in 2026, with a projected return to profitability in 2026 [3][39]. - The report anticipates steady growth in digital medical insurance and digital healthcare segments, with revenue growth rates of 10% and 50% respectively over the next few years [39].

国新健康保障服务集团股份有限公司 投资者关系活动记录表 编号：2024-02 2、请问公司预期 DRG/DIP2.0 政策带来的增量空间有多大？公司在 这方面有哪些进展？ 答：DRG/DIP2.0 版通过对分组条件、数量和内容等进行优化， 使得分组更加精准、更加贴合临床实际，同时明确基金预付、特病单 议、除外支付等工作机制，并要求 2025 年各统筹地区统一使用新分 组版本，提高支付方式改革的规范性和统一性，可以说全面优化了 DRG/DIP 支付方式改革的工作机制同时，新版本的分组方案也为医 疗机构病种结构优化提供了更加精细化的管理工具，能够帮助医院动 态调整病种结构、优化病种管理，以病种为切入点优化医院精细化运 营管理，新版本分组方案的发布在系统更新、数据服务等方面为医保 端和院端都带来新的一轮需求增量。 在 DRG/DIP2.0 政策的引领下，国新健康成功研发了新一代分组 器，并开展了多轮内部及客户培训，以深化团队成员对政策的理解和 技术应用能力。同时，公司正积极推进与 DRG/DIP 监管规则相关的 开发工作，旨在确保医疗服务质量和合规。这些策略性举措体现了国 新健康对政策变化的快速响应，以及对提升产品 ...

证券简称：国新健康 证券代码：000503 编号：2024-68 国新健康保障服务集团股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国新健康保障服务集团股份有限公司（以下简称"公司"）于 2024 年 8 月 29 日在巨潮资讯网（http://www.cninfo.com.cn）披露了《2024 年半年度报告》及 其摘要。为使投资者及时了解公司经营情况，公司将于 2024 年 9 月 20 日下午 15:00 至 16:00 通过电话会议方式举行 2024 年半年度业绩说明会。电话会议拨入 方式如下，请扫描下方二维码报名参会： | 地点 | 会议拨入号码 | | --- | --- | | 中国内地 | 400 810 8228 | | 中国香港 | +852 30051355 | | 参会密码：70758017 | | 特此公告。 (参会报名二维码) 国新健康保障服务集团股份有限公司 董 事 会 二零二四年九月十二日 出席本次说明会的公司人员有：党委书记、董事长李永华先生，党委副书记、 董事、总 ...

证券简称：国新健康 证券代码：000503 编号：2024-64 国新健康保障服务集团股份有限公司 表决情况：3票赞成、0票反对、0票弃权。 具体内容详见同日在《中国证券报》《上海证券报》《证券时报》及巨潮 资讯网（网址：www.cninfo.com.cn）披露的《2024年半年度报告摘要》（公告 编号：2024-65），和在巨潮资讯网（网址：www.cninfo.com.cn）披露的《2024 年半年度报告》。 二、公司2024年半年度募集资金存放与使用情况专项报告 经审核，监事会认为董事会出具的《2024年半年度募集资金存放与使用情 况专项报告》真实、准确、完整地反映了公司募集资金存放与使用的相关情况， 符合中国证监会、深圳证券交易所及公司规章制度的相关规定，不存在募集资 金存放、使用、管理及披露违规的情形。 第十一届监事会第二十三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国新健康保障服务集团股份有限公司（以下简称"公司"）第十一届监事 会第二十三次会议于2024年8月16日发出会议通知，会议由监事会主席周蔚女士 召集并主持，于202 ...